Zoll gains FDA OK for public use defibrillator:
This article was originally published in Clinica
Executive Summary
Zoll Medical has gained FDA 510(k) approval to market its automated external defibrillator in the US for the emergency treatment of sudden cardiac arrest. The battery-powered Zoll AED Plus device, which features simple, step by step illustrations and audio coaching, is designed to be easy to use for the lay person to assist heart attack victims. It is the first AED to use a single electrode pad that is easy to position on the victim's body, said the Burlington, Massachusetts firm.
You may also be interested in...
Jefferies' Survey Predicts M&A Rebound In 2021
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: